Lawmakers from member states of the European Union agreed to measures last week to stop drug shortages and fix chronic Asian dependencies for critical medicines, this time spurred by worries over the antibiotics supply chain.
The clock is ticking on the U.S.-Mexico-Canada Agreement. On July 1, 2026, the three parties are scheduled to sit down for the formal “joint review” required by the deal itself. Under the terms USMCA’s drafters wrote into the agreement, the entire arrangement automatically expires on July 1, 2036 unless every government affirmatively recommits to it.
The U.S. Chamber of Commerce usually takes a white-glove approach to criticising their members’ businesses in China. But in a recent study, conducted for the Chamber by the Rhodium Group, there is a marked change of tune.
The Bureau of Economic Analysis released its monthly trade data for March, and despite it being the first full month of the imbroglio in the Strait of Hormuz, imports rose more than exports and the deficit surpassed the three month moving average.
The AI data center buildout has exposed three distinct failures in U.S. trade and industrial policy.
How did China become a near peer competitor with the U.S. on everything from computers to AI platforms to space? Theft and IP violations.
Without secure upstream API and 6-APA production, the United States does not have true antibiotic supply security. With the right policy framework and close coordination with European partners, we can rebuild domestic capacity, strengthen allied production, and secure essential medicines for the long term.
Leadership of the House Select Committee on the CCP is convinced China is stealing American AI models. That’s why China has an OpenAI rival, called DeepSeek, and the Europeans have nothing.
The war in Iran is solar power’s Covid moment.
China holds a rapidly expanding position in the global biologics and biosimilars market, driven by heavy government support, regulatory reforms, and massive investments in biotech hubs like Shanghai and Suzhou.
